Skip to main content

ChemoCentryx Inc (CCXI) Stock Forecast 2025 - AI Price Prediction & Analysis


ChemoCentryx Inc (CCXI) AI Stock Price Forecast & Investment Analysis

ChemoCentryx Inc Stock Price Chart and Technical Analysis

Loading ChemoCentryx Inc interactive price chart and technical analysis...

ChemoCentryx Inc (CCXI) - Comprehensive Stock Analysis & Investment Research

Deep dive into ChemoCentryx Inc's business profile, financial performance, AI predictions, and competitive positioning to make informed investment decisions.

Understanding Company Overview

What this section covers: Essential business information about ChemoCentryx Inc, including sector classification, industry positioning, and organizational structure.

How to interpret: Company size, sector, and employee count provide context for market position and growth potential. Leadership and founding date indicate stability and experience.

For ChemoCentryx Inc: ChemoCentryx Inc operates in the Manufacturing sector, establishing it as a mid-cap growth opportunity.

ChemoCentryx Inc (Stock Symbol: CCXI) is a leading company in the Manufacturing sector , specifically operating within the Pharmaceutical Preparation Manufacturing industry.

The organization employs approximately 133 professionals worldwide and operates under the strategic leadership of CEO Thomas Schall.

The company has established itself as a growing mid-cap opportunity with strong fundamentals.

Understanding Financial Performance

What these metrics mean: Key financial indicators showing ChemoCentryx Inc's revenue scale, profitability, market value, and shareholder returns.

How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.

For ChemoCentryx Inc: With $9M in annual revenue and -1146.7% net margin, the company demonstrates developing profitability.

Annual Revenue: $9 million generating a -1146.7% net profit margin .

Market Capitalization: $3709 million - Classified as a mid-cap growth stock with balanced risk-reward profile.

Return on Equity (ROE): -45.4% - Below-average shareholder return efficiency, indicating areas for operational improvement.

Understanding AI Stock Predictions

What these predictions mean: AI-powered forecasts for ChemoCentryx Inc stock using machine learning algorithms trained on historical market data and technical indicators.

How to interpret: Positive percentages indicate expected price increases, negative values suggest potential declines. Spearman correlation coefficient shows the statistical relationship between predictions and actual outcomes.

For ChemoCentryx Inc: Unlock premium access to view detailed AI predictions and price targets.

🚀 Unlock Premium AI Predictions to access our advanced machine learning forecasts for ChemoCentryx Inc stock, including 7-day, 30-day, and 90-day price targets with confidence intervals and risk assessments.

Understanding Market Position

What this analysis covers: ChemoCentryx Inc's competitive positioning, market dynamics, operational efficiency, and strategic advantages within its industry.

How to evaluate: Strong cash flow generation, healthy margins, and market leadership indicate competitive advantages. Growth rates show expansion potential.

For ChemoCentryx Inc: Market positioning analysis based on available financial and operational metrics.

ChemoCentryx Inc strategically competes in the highly dynamic Pharmaceutical Preparation Manufacturing marketplace, establishing itself as a promising mid-cap growth opportunity with strong fundamentals and expanding market share .

The company maintains a healthy 98.1% gross margin, indicating strong pricing power and operational efficiency.

ChemoCentryx Inc (CCXI) Fundamental Analysis & Insider Trading Data (Quarterly Financial Reports)

Comprehensive quarterly financial data, earnings trends, insider transactions, and institutional holdings for ChemoCentryx Inc stock analysis.

Loading ChemoCentryx Inc comprehensive fundamental analysis and insider trading data...

Deep dive into ChemoCentryx Inc's financial health, valuation metrics, and operational efficiency to make informed investment decisions.

Understanding Valuation Metrics

What these metrics mean: Valuation metrics help determine if ChemoCentryx Inc stock is fairly priced compared to its earnings, assets, and market position.

How to read them: Lower P/E ratios may indicate undervalued stocks, while higher ratios suggest growth expectations. P/B ratio compares market value to book value.

For ChemoCentryx Inc: With a P/E ratio of -24.31, the market sees the stock as potentially undervalued.

P/E Ratio -24.31x
P/B Ratio 15.68x
Market Cap $3709M
EPS $-1.00
Book Value/Share $3.32
Revenue/Share $0.27
FCF/Share $-1.40
Understanding Profitability Metrics

What these metrics mean: These ratios measure how efficiently ChemoCentryx Inc converts revenue into profit and generates returns for shareholders.

How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.

For ChemoCentryx Inc: An ROE of -45.4% indicates room for improvement in shareholder value creation.

ROE -45.4%
ROA -29.9%
ROIC -36.4%
Gross Margin 98.1%
Operating Margin -1379.2%
Net Margin -1146.7%
EBT Margin -518.3%
Understanding Financial Health Metrics

What these metrics mean: These ratios assess ChemoCentryx Inc's ability to meet short-term obligations and manage debt levels effectively.

How to read them: Current ratio >2 is generally good, Quick ratio >1 shows strong liquidity. Lower D/E ratios indicate conservative debt management.

For ChemoCentryx Inc: A current ratio of 5.11 indicates strong liquidity.

Current Ratio 5.11x
Quick Ratio 4.99x
D/E Ratio 0.20x
Financial Leverage 1.70x
Interest Coverage -53.0x
Working Capital $390M
Understanding Cash Flow Metrics

What these metrics mean: Cash flow metrics reveal ChemoCentryx Inc's ability to generate cash from operations and fund growth initiatives.

How to read them: Positive operating cash flow is crucial. Free cash flow shows money available for dividends, buybacks, or investments.

For ChemoCentryx Inc: Free cash flow of $-54M indicates cash challenges that need attention.

Operating Cash Flow $-45M
Free Cash Flow $-54M
Capital Spending $-8M
OCF Growth YoY 236.9%
FCF Growth YoY 275.4%
FCF/Sales -197.5%
CapEx/Sales 30.8%
Understanding Operational Efficiency Metrics

What these metrics mean: These ratios measure how effectively ChemoCentryx Inc uses its assets and manages working capital.

How to read them: Higher turnover ratios indicate efficient asset utilization. Shorter collection periods show effective credit management.

For ChemoCentryx Inc: An asset turnover of 0.06x suggests room for improvement in asset utilization.

Asset Turnover 0.06x
Receivables Turnover 4.2x
Inventory Turnover 0.2x
Fixed Assets Turnover 0.5x
Days Sales Outstanding 87 days
Days Inventory 2086 days
Payables Period 5885 days
Cash Conversion Cycle -3712 days
Understanding Financial Statement Data

What these metrics mean: Key figures from ChemoCentryx Inc's income statement and balance sheet showing absolute financial performance.

How to read them: Revenue shows business scale, while margins indicate profitability. Balance sheet items reveal financial structure.

For ChemoCentryx Inc: With annual revenue of $9M, ChemoCentryx Inc represents a smaller but potentially high-growth operation.

Income Statement ($ Millions)
Total Revenue $9M
Operating Income $-131M
Net Income $-109M
R&D Expense $71M
SG&A Expense $327M
Cost of Goods Sold $2M
Balance Sheet Highlights (% Of Assets)
Total Current Assets 80%
Cash & Short-term Investments 77%
Total Liabilities 41%
Short-term Debt 4%
Accounts Receivable 1%
Inventory 1%
Dividend & Shareholder Information
Shares Outstanding 71M
Growth Metrics (YoY)
EPS Growth -1.9%

Latest ChemoCentryx Inc Stock News & Market Analysis

Breaking news, analyst reports, and market updates affecting ChemoCentryx Inc (CCXI) stock price and investment outlook.

, source: Nasdaq

Aug 4 (Reuters) - Amgen Inc AMGN.O said on Thursday it would buy ChemoCentryx Inc CCXI.O for $3.7 billion to gain access to the company's anti-inflammation drug. Amgen will pay $52 per share in cash, ...

, source: Benzinga.com

A ChemoCentryx press release announced that Amgen, Inc. AMGN has acquired the company in an all-cash deal. The $3.7-billion acquisition has a value of $52 per share, which is causing the stock price ...

, source: AOL

At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (see why hell is coming). We reversed our stance ...

, source: Seeking Alpha

SAN CARLOS, Calif., May 31, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. (CCXI), (Nasdaq: CCXI), today announced changes to the composition of its Board of Directors. David E. Wheadon, M.D., has been ...

, source: Law

In what could turn out to be one of the largest drug deals of 2006, U.S. biotech firm ChemoCentryx, Inc., stands to enjoy a $1.5 billion paydayif it meets targets in developing and marketing its new ...

ChemoCentryx Inc Competitors & Peer Analysis - Manufacturing Sector

Comparative analysis of ChemoCentryx Inc against industry peers and competitors in the Manufacturing sector, featuring AI-powered forecasts and key financial metrics.

Company Ticker Symbol 90-Day AI Forecast Market Cap (USD M) P/E Ratio P/B Ratio

Frequently Asked Questions - ChemoCentryx Inc Stock Forecast

How accurate are ChemoCentryx Inc stock predictions?

Our AI model shows a 8500% Spearman correlation coefficient for CCXI predictions, based on advanced machine learning algorithms trained on over 10 years of market data. This measures the strength of the monotonic relationship between predicted and actual price movements.

What factors influence ChemoCentryx Inc stock price forecasts?

Our analysis considers ChemoCentryx Inc's financial metrics, Manufacturing sector trends, market sentiment, technical indicators, earnings data, and macroeconomic factors affecting stock performance.

Is ChemoCentryx Inc a good investment in 2025?

Based on our AI analysis, ChemoCentryx Inc shows potential for various market scenarios. Consider your risk tolerance, investment timeline, and portfolio diversification before making investment decisions.

How often are ChemoCentryx Inc forecasts updated?

ChemoCentryx Inc stock forecasts are updated daily using real-time market data, ensuring you receive the most current AI-powered predictions and investment insights.

Want More Advanced ChemoCentryx Inc Analysis?

Unlock premium features including detailed price targets, risk assessments, portfolio optimization, and real-time alerts for ChemoCentryx Inc stock.

My Portfolio

Investment Dashboard

Loading your portfolio...